<?xml version="1.0" encoding="UTF-8" ?><rss version="2.0"><channel><title><![CDATA[Novo Nordisk A/S - Press Releases]]></title><description><![CDATA[Novo Nordisk A/S - Press Releases]]></description><link><![CDATA[http://www.novonordisk.com/]]></link><item><title><![CDATA[New data demonstrate Victoza® (liraglutide) provided superior and sustained blood sugar control and weight reduction compared to Januvia® (sitagliptin) at 52 weeks]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=77c90b80-eaa0-474b-96ab-512e22a9c96b&sShowLanguageCode=en-GB&csref=RSS_New_data_demonstrate_Victoza®_liraglutide_provided_superior_and_sustained_blood_sugar_control_and_weight_reduction_compared_to_Januvia®_sitagliptin_at_52_weeks]]></link><description><![CDATA[Orlando, FL – Poster 16LB – Late-breaking Novo Nordisk extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily Victoza® in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose (FPG) than Januvia® plus metformin at 52 weeks.]]></description></item><item><title><![CDATA[Phase 2 data for ultra-long-acting insulin degludec show the potential to effectively lower blood sugar, including when used three times a week]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=8ab3af8b-0958-44c3-9f86-cb9ca5ba960b&sShowLanguageCode=en-GB&csref=RSS_Phase_2_data_for_ultra-long-acting_insulin_degludec_show_the_potential_to_effectively_lower_blood_sugar_including_when_used_three_times_a_week]]></link><description><![CDATA[Orlando, FL – Novo Nordisk today presented phase 2 proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycaemic control when used once daily or three times weekly. These data were presented at the 70th Scientific Sessions of the American Diabetes Association (ADA).1]]></description></item><item><title><![CDATA[Victoza® to be launched in Japan in June]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=8e3ba3d5-0215-4ecf-9520-62a1d09297cd&sShowLanguageCode=en-GB&csref=RSS_Victoza®_to_be_launched_in_Japan_in_June]]></link><description><![CDATA[]]></description></item><item><title><![CDATA[Novo Nordisk partners with international scientific community for Victoza® cardiovascular outcomes trial]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=5eee2c75-b2fd-459b-bfee-254fd8762462&sShowLanguageCode=en-GB&csref=RSS_Novo_Nordisk_partners_with_international_scientific_community_for_Victoza®_cardiovascular_outcomes_trial]]></link><description><![CDATA[]]></description></item><item><title><![CDATA[The Lancet publishes new data demonstrating the superior efficacy of Victoza® (liraglutide) compared to Januvia® (sitagliptin) in the treatment of type 2 diabetes]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=b5d4774f-07d4-45d4-b40d-42f92fff7c74&sShowLanguageCode=en-GB&csref=RSS_The_Lancet_publishes_new_data_demonstrating_the_superior_efficacy_of_Victoza®_liraglutide_compared_to_Januvia®_sitagliptin_in_the_treatment_of_type_2_diabetes]]></link><description><![CDATA[]]></description></item><item><title><![CDATA[Novo Nordisk launches international survey into the psychosocial effects of living with haemophilia]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=3f865f23-3213-4031-ab23-1280ae6dda59&sShowLanguageCode=en-GB&csref=RSS_Novo_Nordisk_launches_international_survey_into_the_psychosocial_effects_of_living_with_haemophilia]]></link><description><![CDATA[Novo Nordisk announced today the start of a global survey into the psychological and social effects of haemophilia. The study, named HERO (Haemophilia Experiences, Results and Opportunities), will assess factors such as the attitudes of patients and their families to diagnosis and treatment, their aspirations and the social context of haemophilia. The study will include responses from over 1,300 people from 12 countries, and is the largest international research project ever carried out into the social and psychological impact of this condition. ]]></description></item><item><title><![CDATA[Novo Nordisk receives FDA approval for Norditropin® FlexPro® for growth hormone treatment]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=9f5a8483-c572-44c9-b820-e83233d010c0&sShowLanguageCode=en-GB&csref=RSS_Novo_Nordisk_receives_FDA_approval_for_Norditropin®_FlexPro®_for_growth_hormone_treatment]]></link><description><![CDATA[]]></description></item><item><title><![CDATA[Minister presents scholarships to young research talents]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=3eb59bbd-4aed-46b8-8e63-d48c41e5aeca&sShowLanguageCode=en-GB&csref=RSS_Minister_presents_scholarships_to_young_research_talents]]></link><description><![CDATA[Today, Helge Sander, Minister for Science, Technology and Innovation, presented scholarships totalling 2.5 million Danish kroner to 38 of the country's most talented young students in biomedical, pharmaceutical and biotechnological sciences on behalf of two of Denmark's leading research companies, Novo Nordisk and Novozymes, which together invested 8.8 billion kroner in research and development in 2008. The scholarships are part of the Novo Scholarship Programme, operated jointly by the two companies. ]]></description></item><item><title><![CDATA[Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=acc555cc-2124-4ebf-ad6d-7f923e2e2a78&sShowLanguageCode=en-GB&csref=RSS_Novo_Nordisk_starts_phase_1_trial_with_long-acting_oral_GLP-1_analogue]]></link><description><![CDATA[]]></description></item><item><title><![CDATA[Novo Nordisk and Combine in research collaboration for the treatment of autoimmune diseases]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=d280f398-7596-49a1-9da2-a7c5f2aa92a4&sShowLanguageCode=en-GB&csref=RSS_Novo_Nordisk_and_Combine_in_research_collaboration_for_the_treatment_of_autoimmune_diseases]]></link><description><![CDATA[Novo Nordisk and the Swedish university consortium Combine announced today a research collaboration in the field of autoimmune diseases. ]]></description></item><item><title><![CDATA[Novo Nordisk licenses IL-21 mAb and patent rights to IL-21 antibodies from ZymoGenetics]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=c40eb302-78eb-4745-868c-37473b0dd089&sShowLanguageCode=en-GB&csref=RSS_Novo_Nordisk_licenses_IL-21_mAb_and_patent_rights_to_IL-21_antibodies_from_ZymoGenetics]]></link><description><![CDATA[24 million US dollars upfront payment with 157.5 million dollars of total potential milestone payments ]]></description></item><item><title><![CDATA[Novo Nordisk starts phase 1 trial with oral insulin analogue]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=7f93ad06-681a-4f65-8e34-974765368874&sShowLanguageCode=en-GB&csref=RSS_Novo_Nordisk_starts_phase_1_trial_with_oral_insulin_analogue]]></link><description><![CDATA[Merrion Pharmaceuticals earns USD 2 million milestone payment]]></description></item><item><title><![CDATA[EFSD/Novo Nordisk partnership for diabetes research in Europe]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=0896d0b5-9568-4419-bea9-ea5804be39c3&sShowLanguageCode=en-GB&csref=RSS_EFSDNovo_Nordisk_partnership_for_diabetes_research_in_Europe]]></link><description><![CDATA[Three million euros to support European diabetes research  ]]></description></item><item><title><![CDATA[Novo Nordisk extends programme of free insulin and diabetes care to reach 700 children in Bangladesh]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=64db2355-8789-4d8b-bfe4-a66bf4088a70&sShowLanguageCode=en-GB&csref=RSS_Novo_Nordisk_extends_programme_of_free_insulin_and_diabetes_care_to_reach_700_children_in_Bangladesh]]></link><description><![CDATA[]]></description></item><item><title><![CDATA[New study results show that patients have higher treatment satisfaction with liraglutide compared to exenatide]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=7aa8bd5b-4af4-4ef9-a030-78113ee483bd&sShowLanguageCode=en-GB&csref=RSS_New_study_results_show_that_patients_have_higher_treatment_satisfaction_with_liraglutide_compared_to_exenatide]]></link><description><![CDATA[Montreal, Canada – New data on patient treatment satisfaction from the LEAD™ 6 trial presented today at the 20th World Diabetes Congress (International Diabetes Federation) shows that patients have higher overall treatment satisfaction with liraglutide than they do with exenatide.  ]]></description></item><item><title><![CDATA[The 4-T study of intensified insulin regimens shows excellent three-year glucose control with low risk of hypoglycaemia in type 2 diabetes]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=0c6c3dc7-71fe-4e42-955c-01027a0655ad&sShowLanguageCode=en-GB&csref=RSS_The_4-T_study_of_intensified_insulin_regimens_shows_excellent_three-year_glucose_control_with_low_risk_of_hypoglycaemia_in_type_2_diabetes]]></link><description><![CDATA[A long-awaited study presented today at the International Diabetes Federation World Diabetes Congress in Montreal, Canada, has shown that it is possible for patients with type 2 diabetes to achieve good blood glucose control with a very low rate of major hypoglycaemia  even as they intensify their insulin treatment. The results of the ‘Treating to Target in Type 2 Diabetes’ (4-T) study that compared three different insulin treatment regimens over three years were also published online today by the New England Journal of Medicine.]]></description></item><item><title><![CDATA[New data shows that type 2 diabetes patients who start insulin therapy with once-daily NovoMix® 30 achieve significantly greater HbA1c reduction than with insulin glargine. 1]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=b06517bc-aee5-4fb1-9324-2dedc38910e6&sShowLanguageCode=en-GB&csref=RSS_New_data_shows_that_type_2_diabetes_patients_who_start_insulin_therapy_with_once-daily_NovoMix®_30_achieve_significantly_greater_HbA1c_reduction_than_with_insulin_glargine._1]]></link><description><![CDATA[Vienna, Austria - Data from a new study presented today at the annual meeting of the European Association for the Study of Diabetes (EASD) shows that type 2 diabetes patients starting insulin treatment with once-daily injection of NovoMix® 30 (biphasic insulin aspart) achieve a significantly greater HbA1c reduction compared to patients starting with a daily injection of insulin glargine. Treatment with NovoMix® 30 also resulted in significantly lower blood glucose levels after dinner and at bedtime, as compared to insulin glargine. 1]]></description></item><item><title><![CDATA[New data shows that patients with type 2 diabetes improve their blood sugar control when switched to Victoza® from Byetta®]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=d9331382-8fa0-409b-b32a-7e4b84032b1b&sShowLanguageCode=en-GB&csref=RSS_New_data_shows_that_patients_with_type_2_diabetes_improve_their_blood_sugar_control_when_switched_to_Victoza®_from_Byetta®]]></link><description><![CDATA[Vienna, Austria - New data from the extension phase of the LEAD™ 6 phase 3b study presented today at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) shows that patients with type 2 diabetes further improved their treatment outcome by switching from two daily injections of Byetta® (exenatide, 10 µg dose) to one daily injection of Victoza® (liraglutide, 1.8 mg dose).]]></description></item><item><title><![CDATA[Novo Nordisk opens new research centre in Seattle]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=7947ef3e-9199-4c47-b4eb-ef7c77923429&sShowLanguageCode=en-GB&csref=RSS_Novo_Nordisk_opens_new_research_centre_in_Seattle]]></link><description><![CDATA[Novo Nordisk announced today the official opening of the company’s new inflammation research centre based in Seattle. ]]></description></item><item><title><![CDATA[Novo Nordisk reaches settlement with the Danish authorities regarding Oil-for-Food activities]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=6f5581f7-a9f0-4f3a-b914-d5335dc0feeb&sShowLanguageCode=en-GB&csref=RSS_Novo_Nordisk_reaches_settlement_with_the_Danish_authorities_regarding_Oil-for-Food_activities]]></link><description><![CDATA[Novo Nordisk announced today that it has reached a settlement with the Danish Public Prosecutor for Serious Economic Crime regarding the company’s sales to Iraq during 2000 to 2003 under the United Nations Oil-for-Food programme. Under the terms of the settlement, Novo Nordisk will pay back past profits of 30 million Danish kroner. ]]></description></item></channel></rss>